■我们首次进行了这种汇总分析,以全面探索肿瘤相关高内皮小静脉(TA-HEV)的预后价值,并确定其与实体肿瘤临床病理特征的关系。
■四个在线数据库,包括PubMed,WebofScience,Embase,和Cochrane图书馆,进行了全面搜索,以确定评估TA-HEV对预后或临床病理特征影响的研究。使用95%置信区间(CI)的危险比(HR)评估生存结果。包括总生存期(OS),无病生存率(DFS),无进展生存期(PFS),癌症特异性生存率(CSS)。TA-HEV状态与临床病理特征之间的关联通过比值比(ORs)结合95%CI进行评估。进行亚组分析以探索异质性的来源。进行敏感性分析以评估我们研究结果的稳定性。同时,漏斗图被用来直观地评估潜在的出版偏倚,并采用Begg\和Egger\的测试来定量确定发表偏倚。
■共有13项回顾性队列研究,最终将1,933例患者纳入本荟萃分析.效应-大小汇集分析显示,TA-HEV阳性与OS改善相关(汇集HR:0.75,95%CI:0.62-0.93,P<0.01),和DFS(合并HR=0.54,95%CI=0.41-0.72,P<0.01)。然而,实体肿瘤中TA-HEV阳性与PFS(合并HR=0.75,95%CI0.34-1.64,P=0.47)或CSS(合并HR:0.58,95%CI:0.04-7.58,P=0.68)无关。进一步的亚组分析表明,种族和HR来源是导致异质性的主要因素。此外,TA-HEV与淋巴结转移和远处转移呈负相关,但与较差的肿瘤分化呈正相关。然而,TA-HEV与性别无显著相关性,LVI,临床分期,入侵的深度。敏感性分析表明,合并结果稳定可靠,在所有纳入的文章中没有显著的发表偏倚。
■这是首次使用现有文献对TA-HEV在实体瘤中的预后价值进行综合分析。总的来说,我们的研究表明TA-HEV与预后和临床病理特征之间存在显著相关性.TA-HEV可作为新型免疫相关生物标志物用于实体肿瘤的临床评估和预后预测。
■https://www.crd.约克。AC.uk/prospro/display_record.php,标识符CRD42023394998。
UNASSIGNED: We performed this pooled analysis for the first time to comprehensively explore the prognostic value of tumor-associated high endothelial
venules (TA-HEVs) and determine their relationships with clinicopathological features in solid tumors.
UNASSIGNED: Four online databases, including PubMed, Web of Science, Embase, and Cochrane Library, were comprehensively searched to identify studies assessing the effect of TA-HEVs on prognosis or clinicopathological features. Hazard ratios (HRs) with 95% confidence intervals (CIs) were applied to evaluate survival outcomes, including overall survival (OS), disease-free survival (DFS), progression-free survival (PFS), and cancer-specific survival (CSS). The association between TA-HEV status and clinicopathological characteristics was assessed by odds ratios (ORs) combined with 95% CIs. Subgroup analysis was conducted to explore sources of heterogeneity. The sensitivity analysis was performed to evaluate the stability of our findings. Meanwhile, Funnel plots were employed to visually evaluate potential publication bias, and both Begg\'s and Egger\'s tests were adopted to quantitatively determine publication bias.
UNASSIGNED: A total of 13 retrospective cohort studies, involving 1,933 patients were finally included in this meta-analysis. Effect-size pooling analysis showed that the positivity of TA-HEVs was related to improved OS (pooled HR: 0.75, 95% CI: 0.62-0.93, P<0.01), and DFS (pooled HR = 0.54, 95% CI = 0.41-0.72, P< 0.01). However, TA-HEV positivity in solid tumors was not linked to PFS (pooled HR = 0.75, 95% CI 0.34-1.64, P = 0.47) or CSS (pooled HR: 0.58, 95% CI: 0.04-7.58, P= 0.68). Further subgroup analysis demonstrated that ethnicity and source of HR were the main factors contributing to heterogeneity. Moreover, TA-HEVs were inversely associated with lymph node metastasis and distant metastasis, but were positively related to worse tumor differentiation. However, TA-HEVs were not significantly correlated with sex, LVI, clinical stage, and depth of invasion. Sensitivity analysis suggested that the pooled results were stable and reliable, with no significant publication bias in all included articles.
UNASSIGNED: This is the first comprehensive analysis of the prognostic value of TA-HEVs in solid tumors using existing literature. Overall, our study demonstrated a significant correlation between TA-HEVs and prognosis as well as clinicopathological features. TA-HEVs may serve as novel immune-related biomarkers for clinical assessments and prognosis prediction in solid tumors.
UNASSIGNED: https://www.crd.york.ac.uk/prospero/display_record.php, identifier CRD42023394998.